Tirzepatide Side Effects: What to Expect on Zepbound and Mounjaro

Common Tirzepatide Side Effects at a Glance

Tirzepatide—the molecule in Zepbound (approved for chronic weight management) and Mounjaro (approved for type 2 diabetes)—is the first dual GIP and GLP-1 receptor agonist. Its most common side effects are gastrointestinal and, in large randomized controlled trials including SURMOUNT-1 and the SURPASS program, affected a substantial proportion of participants at higher doses.

• Nausea — the most frequently reported adverse event across all doses
• Diarrhea — common, especially early in treatment
• Constipation — reported at rates similar to diarrhea in SURMOUNT-1
• Vomiting — less frequent than nausea but meaningful at higher doses
• Dyspepsia and indigestion — bloating, heartburn, upper abdominal discomfort
• Decreased appetite — an expected pharmacodynamic effect, sometimes captured as an adverse event in trial reporting

These effects are dose-dependent: they occur more often and more intensely at 10 mg and 15 mg than at the 2.5 mg starting dose. In SURMOUNT-1, roughly a quarter to a third of participants on the highest dose reported nausea at some point during the trial, compared with a much smaller proportion on placebo.

Nausea: What to Expect and How It Typically Fades

Nausea is the single most commonly reported adverse event during tirzepatide therapy. It follows a predictable pattern for most patients:

• Onset typically occurs in the first one to three days after each dose increase
• Severity peaks during the escalation phase and gradually eases as the body adapts
• Most patients find nausea is substantially reduced or absent once they have been stable on a dose for several weeks

In SURMOUNT-1, gastrointestinal adverse events led to treatment discontinuation in a small minority of participants—indicating that the majority tolerated the drug through the titration phase. Practical measures that may help include eating smaller, lower-fat meals; avoiding spicy or high-fiber foods during active nausea; eating slowly and stopping before feeling overly full; and, if morning nausea is bothersome, experimenting with taking the injection in the evening.

Diarrhea and Constipation

Both diarrhea and constipation are common and can sometimes alternate in the same patient. Diarrhea was reported by a meaningful proportion of participants in SURMOUNT-1 and the SURPASS trials, often within the first weeks of a dose step-up. It is usually mild to moderate in severity and self-limiting.

Constipation was also frequently reported in SURMOUNT-1—in some dose arms at rates similar to diarrhea. The primary mechanism is likely tirzepatide's slowing of gastric and colonic motility.

• For diarrhea: stay well hydrated, limit high-fat or greasy foods, and contact your provider if symptoms are severe or persist beyond a few days
• For constipation: increase fluid intake, incorporate gentle physical activity, and consider fiber-rich foods if tolerated—discuss with your provider before starting laxatives

Severe or prolonged diarrhea can contribute to dehydration, which in turn raises the risk of acute kidney injury.

Injection-Site Reactions and Other Common Effects

Beyond gastrointestinal symptoms, the following adverse effects have been reported in clinical trials and post-marketing experience:

• Injection-site reactions — redness, swelling, itching, or bruising; generally mild and self-resolving. Rotating the site each week (abdomen, upper thigh, or upper arm) helps minimize recurrence.
• Fatigue — reported by some patients, particularly early in treatment or during dose escalation
• Abdominal pain — may overlap with the GI side-effect profile; persistent or severe abdominal pain should be evaluated by a provider
• Acid reflux or belching — related to slowed gastric emptying
• Hair thinning (telogen effluvium) — reported with rapid weight loss from any cause; not specific to tirzepatide and usually temporary

In both the SURMOUNT and SURPASS trials, most non-GI adverse events were mild to moderate in severity and rarely led to discontinuation.

Why Side Effects Are Most Intense During Dose Escalation

Tirzepatide is initiated at a low dose—2.5 mg once weekly—and increased in 2.5 mg increments approximately every four weeks until the therapeutic maintenance dose (5 mg, 10 mg, or 15 mg) is reached. This gradual titration schedule is intentional: it allows the gastrointestinal tract time to accommodate the drug's effects on gastric emptying and satiety signaling.

Despite this stepwise approach, most GI side effects are most pronounced in the days immediately following each dose increase. Once the dose stabilizes, gastric accommodation improves and symptoms diminish for the majority of patients. If GI side effects are intolerable at a given dose step, it is both safe and common practice to pause the escalation—remaining at the lower dose for an additional four to eight weeks—before attempting to move up again. This decision should always be made in consultation with your prescribing provider.

Serious but Uncommon Risks: Pancreatitis, Gallbladder Disease, and Kidney Injury

While most tirzepatide side effects are manageable, several uncommon events can be serious and require prompt medical attention:

• Acute pancreatitis — GLP-1-class therapies carry a prescribing label warning for pancreatitis. The absolute risk is low, but sudden, severe abdominal pain—especially if it radiates to the back and is accompanied by vomiting—warrants emergency evaluation. Stop the medication and seek care immediately if this occurs.
• Gallbladder disease (cholelithiasis and cholecystitis) — Rapid weight loss from any cause increases the risk of gallstone formation. Both SURMOUNT trials and the broader GLP-1 literature have documented higher rates of gallbladder-related adverse events with active treatment compared with placebo. Symptoms include right upper abdominal pain (especially after fatty meals), nausea, and fever.
• Acute kidney injury — Significant dehydration from severe vomiting or diarrhea can impair kidney perfusion. Risk is higher in patients already taking ACE inhibitors, ARBs, or NSAIDs. Maintaining adequate fluid intake is the primary preventive measure, particularly during a GI flare.

Boxed Warning: Thyroid C-Cell Tumors

Tirzepatide's FDA-approved prescribing label carries a boxed warning—the agency's most prominent safety alert—regarding thyroid C-cell tumors. In rodent studies, tirzepatide caused dose- and duration-dependent medullary thyroid carcinoma (MTC). It has not been established whether tirzepatide causes MTC in humans.

Because of this preclinical signal, tirzepatide is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

If you or a close blood relative has had MTC or MEN2, tirzepatide should not be used. Disclose any thyroid history to your provider before starting. Routine thyroid monitoring is not required for patients without these risk factors, but any new neck lump, persistent hoarseness, difficulty swallowing, or throat discomfort should be reported to your provider promptly.

Hypoglycemia: Low Risk Alone, Higher With Certain Drug Combinations

Tirzepatide stimulates insulin secretion in a glucose-dependent manner—meaning its insulin-releasing effect diminishes as blood glucose approaches normal levels. This mechanism substantially limits the risk of hypoglycemia when tirzepatide is used as monotherapy.

The risk increases meaningfully when tirzepatide is combined with:

• Insulin — In SURPASS-5 and related insulin-combination trials, adding tirzepatide to existing insulin therapy was associated with a higher incidence of symptomatic hypoglycemia. Insulin doses typically need to be reduced when tirzepatide is initiated; your provider should guide this adjustment.
• Sulfonylureas (e.g., glipizide, glimepiride, glyburide) — These drugs stimulate insulin release regardless of blood glucose, and combining them with tirzepatide raises hypoglycemia risk. Your provider may reduce or discontinue the sulfonylurea when tirzepatide is started.

Know the signs of low blood sugar: shakiness, sweating, rapid heartbeat, confusion, and hunger. If you take insulin or a sulfonylurea alongside tirzepatide, keep a fast-acting carbohydrate accessible at all times.

How to Reduce Side Effects, Who Should Not Take Tirzepatide, and When to Seek Care

Practical strategies to minimize side effects:

• Eat smaller, lower-fat meals and avoid greasy, heavily spiced, or very high-fiber foods during active GI symptoms
• Eat slowly and stop when comfortably full—not stuffed
• Stay well hydrated, especially when nausea, vomiting, or diarrhea is present
• Rotate injection sites each week to prevent local reactions
• Ask your provider about pausing dose escalation if GI effects are intolerable—this is a recognized and effective management approach

Tirzepatide vs. semaglutide GI tolerability: Data from SURPASS-2—a head-to-head trial comparing tirzepatide with semaglutide 1 mg weekly in type 2 diabetes—found broadly similar rates of GI adverse events, with neither drug clearly better tolerated than the other. Individual responses vary, and some patients tolerate one agent considerably better than the other.

Who should not take tirzepatide: People with a personal or family history of MTC or MEN2 (absolute contraindication); those with known hypersensitivity to tirzepatide or any excipient; and pregnant individuals, as weight-loss pharmacotherapy is not recommended during pregnancy. A prior history of pancreatitis or gallbladder disease should be discussed with your provider.

A note on compounded tirzepatide: Compounded versions of tirzepatide are not FDA-approved and were not included in SURMOUNT, SURPASS, or any other regulated clinical trial. They are not held to the same manufacturing standards for purity, potency, and sterility as FDA-approved branded products, and their safety and efficacy have not been independently verified. Discuss FDA-approved treatment options with your provider.

When to contact your provider urgently or seek emergency care:

• Severe or unrelenting vomiting or diarrhea, or signs of dehydration (dark urine, extreme dizziness, dry mouth, little to no urination)
• Sudden, severe abdominal pain—possible pancreatitis or gallbladder event
• A new lump or swelling in your neck, persistent hoarseness, or difficulty swallowing
• Symptoms of low blood sugar if you take insulin or a sulfonylurea alongside tirzepatide
• A severe or spreading injection-site reaction (progressive redness, warmth, swelling, or fever)